Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sarepta Therapeutics
Biotech
Sarepta's next DMD drug seems to get the job done in phase 2
Sarepta's next Duchenne muscular dystrophy med seems to be doing the job of spurring dystrophin expression. But does it matter given prior approvals?
Annalee Armstrong
Jan 29, 2024 10:49am
FDA's Marks overrules staff drug reviewers 'with trepidation'
Jul 27, 2023 3:05pm
Santhera offloads North American rights for DMD med to Catalyst
Jun 20, 2023 9:53am
FDA needs more time for Sarepta's DMD gene therapy
May 24, 2023 8:39am
FDA advisers narrowly support Sarepta's DMD gene therapy
May 12, 2023 7:09pm
FDA questions benefits, risks of Sarepta DMD gene therapy
May 10, 2023 11:02am